MRVI
Maravai LifeSciences Holdings, Inc.
MRVI offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has a slight edge over MRVI overall, supported by lower modeled downside and stronger modeled upside.
MRVI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Strong |
MRVI's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
MRVI PE Valuation
MRVI has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
MRVI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
MRVI has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
MRVI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.43 | +$0.44 |
| Q2 2026 | -$0.52 | +$0.87 |
| Q1 2026 | -$0.71 | +$0.46 |
| Q4 2025 | -$0.90 | +$0.15 |
| Q3 2025 | -$0.87 | +$0.77 |
| Q2 2025 | -$1.39 | -$0.40 |
| Q1 2025 | -$1.17 | -$0.18 |
| Q4 2024 | -$1.05 | -$0.15 |
MRVI is still losing money, but far less than before: $0.43 per share over the past year, against $1.64 at its worst in late 2024.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over MRVI on earnings quality, reporting a profit while its opponent remains loss making.
MRVI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $45.9M | +10% |
| Q2 2026 | $51.4M | +8.5% |
| Q1 2026 | $65.8M | +41% |
| Q4 2025 | $49.9M | -12% |
| Q3 2025 | $41.6M | -36% |
| Q2 2025 | $47.4M | -35% |
| Q1 2025 | $46.9M | -27% |
| Q4 2024 | $56.6M | -24% |
MRVI's revenue is recovering but still below its 2022 peak: $46M last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -45% | +54 points |
| Q2 2026 | -29% | +111 points |
| Q1 2026 | -3.3% | +102 points |
| Q4 2025 | -118% | -51 points |
| Q3 2025 | -99% | +161 points |
| Q2 2025 | -140% | -127 points |
| Q1 2025 | -105% | -76 points |
| Q4 2024 | -67% | -57 points |
MRVI's operating margin was −45% last quarter, up 54 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over MRVI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over MRVI on profitability, with a higher operating margin.
MRVI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.5M | +$22.6M |
| Q2 2026 | $3.6M | +$16.8M |
| Q1 2026 | $4.2M | +$18.9M |
| Q4 2025 | -$24.9M | -$4.4M |
| Q3 2025 | -$18.1M | -498% |
| Q2 2025 | -$13.1M | -267% |
| Q1 2025 | -$14.6M | -$493K |
| Q4 2024 | -$20.5M | -$11.5M |
MRVI's free cash flow was −$13M over the past year, against −$66M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over MRVI on cash generation, producing positive trailing cash flow while its opponent burns cash.
MRVI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +1.1M shares |
| 1 year | +3% | +4.4M shares |
| 3 years | +13% | +17.1M shares |
| 5 years | +33% | +36.8M shares |
| Available history | +54% | +52.4M shares |
MRVI has 149M diluted shares, up 3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over MRVI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
MRVI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2023 | -5.9x | Net Cash |
| Q3 2023 | -0.5x | Net Cash |
| Q2 2023 | -0.2x | Net Cash |
| Q1 2023 | -0.2x | Net Cash |
| Q4 2022 | -0.2x | Net Cash |
| Q3 2022 | -0.1x | Net Cash |
| Q2 2022 | -0.0x | Net Cash |
| Q1 2022 | 0.2x | Very low |
MRVI has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
MRVI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.8 | Neutral |
| Stochastic | 55.9 | Neutral |
MRVI's weekly RSI is 59 (neutral) and its Stochastic is 56 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
MRVI PE vs Healthcare Sector
| Metric | MRVI | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MRVI has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
MRVI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.51 | 2.3% above |
| 20 week MA | $7.09 | 8.3% above |
| 50 week MA | $5.11 | 50% above |
| 100 week MA | $4.09 | 88% above |
| 200 week MA | $6.78 | 13% above |
MRVI has the edge over UNH on trend strength, trading above more of its moving averages.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
MRVI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.9 | $29.7 | -0.5% |
| 2021 | $29.7 | $42.0 | +41% |
| 2022 | $42.0 | $14.0 | -67% |
| 2023 | $14.0 | $6.55 | -53% |
| 2024 | $6.55 | $5.50 | -16% |
| 2025 | $5.50 | $3.27 | -41% |
| 2026 YTD | $3.27 | $7.68 | +135% |
MRVI has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.